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Selective iodide uptake and prolonged iodine retention in the thyroid is the basis 
for targeted radioiodine therapy for thyroid cancer patients, however, salivary gland 
dysfunction is the most frequent non-thyroidal complications. In this study we employed 
non-invasive SPECT functional imaging to quantify the temporal dynamics of thyroidal 
and salivary radioiodine accumulation in mice. At 60 min post radionuclide injection, 
radionuclide accumulation in the salivary gland was generally higher than that in thyroid 
due to much larger volume of the salivary gland. However, radionuclide accumulation 
per anatomic unit in the salivary gland was lower than that in thyroid and was 
comparable among mice of different age and gender. Differently, radionuclide 
accumulation per anatomic unit in thyroid varied greatly among mice. The extent of 
thyroidal radioiodine accumulation stimulated by a single dose of exogenous bovine TSH 
(bTSH) in T3-supplemented mice was much less than that in mice received neither bTSH 
nor T3 (non-treated mice), suggesting that the duration of elevated serum TSH level is 
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important to maximize thyroidal radioiodine accumulation. Furthermore, the extent and 
duration of radioiodine accumulation stimulated by bTSH was less in the thyroids of the 
thyroid-targeted RET/PTC1 (Tg-PTC1) mice bearing thyroid tumors compared to the 
thyroids in wild type mice. Lastly, the effect of 17-AAG on increasing thyroidal, but not 
salivary, radioiodine accumulation was validated in both wild type mice and Tg-PTC1 





 The primary function of the thyroid gland is to synthesize thyroid hormones, 
thriiodothyronine (T3) and thyroxine (T4), which play important roles in systemic 
metabolism. Iodine is an essential component of thyroid hormone yet it is frequently not 
abundant in the diet; therefore the thyroid gland has evolved an effective way to sequester 
iodine 20 to 40 times against its concentration gradient from the systemic circulation. 
Iodide is transported into thyroid follicular cells by the sodium iodide symporter (NIS), 
an intrinsic membrane glycoprotein expressed on the basolateral membrane of the thyroid 
follicular cells. Once in the thyroid cells, iodine is incorporated into thyroglobulin (Tg) 
through a process called iodine organification and stored in the follicular lumen of the 
thyroid. Effective radioiodine accumulation in thyroid tissues, mediated by both active 
uptake and organification, has allowed the clinical use of radioiodine to detect and/or 
ablate residual thyroid cancer tissue in patients who have undergone thyroidectomy (see 
review in Shen et al. 2001).   
Both iodide uptake and organification are mainly stimulated by thyrotropin (TSH). 
To selectively induce radioiodine accumulation in thyroid tissues for effective 
radioiodine therapy, TSH is elevated either by T4 withdrawal to induce endogenous 
hypothyroidism or by exogenous administration of recombinant human TSH (rhTSH) 
prior to radioiodine administration (see guidelines published by Copper et al. 2009; 
Luster et al. 2008). However, about 20-30% patients with metastatic thyroid cancer do 
not benefit from radioiodine therapy due to reduced or absent NIS expression/function 
(Caillou et al. 1998; Castro et al. 2001; Oler Et Cerutti 2009; Patel et al. 2002; Ward et al. 
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2003). Thus, it is of clinical importance to identify/develop pharmacological reagents that 
could increase and/or restore radioiodine accumulation in these tumors. As radioiodine 
accumulation is the net outcome of iodide influx and efflux, strategies to increase 
radioiodine accumulation include selectively increase thyroidal iodide influx and/or 
decrease iodide efflux.  
Much effort has been made to identify reagents that increase NIS mRNA levels 
and/or radioiodine accumulation in cultured thyroid cells. DNA methylation inhibitor 5-
azacytidine (Provenzano et al. 2007; Venkataraman et al. 1999) and H-DAC inhibitor  
depsipeptide (Kitazono et al. 2001) appear to modestly increase in NIS mRNA level as 
well as radioiodine accumulation in both thyroid and non-thyroid cancer cells. 
Conversely, pharmacological inhibitors of MAPK or PI3K/Akt signaling pathways were 
reproducibly shown to increase NIS expression/function in immortalized non-
transformed cultured thyroid cells (Garcia Et Santisteban 2002; Knauf et al. 2003; Kogai 
et al. 2008; Vadysirisack et al. 2007; Zaballos et al. 2008). A recent study showed that 
combination treatment of inhibitors for H-DAC, MAPK, and PI3K increased radioiodine 
accumulation in several human thyroid cancer cell lines (Hou et al. 2010), but this 
finding is yet to be confirmed by others. Most importantly, to our knowledge, none of 
these findings have been validated using immune-competent genetically engineered mice 
carrying thyroid tumors surrounded by physiologically/pathologically relevant 
microenvironment. 
Our lab has previously reported that 17-allyamino-17-demothoxygeldanamycin 
(17-AAG) increases NIS-mediated radioiodine accumulation by decreasing iodide efflux 
in NIS-expressing PC Cl3 rat thyroid cells and PC Cl3 cells stably expressing RET/PTC1 
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(Marsee et al. 2004). This finding was subsequently confirmed by another study showing 
that 17-AAG increases iodide retention in cultured human anaplastic thyroid cancer cells 
stably expressing hNIS (Elisei et al. 2006). In our current study, we used non-invasive 
radionuclide imaging with micro-single photon emission computed tomography (micro-
SPECT) to validate the effect of 17-AAG on increasing thyroidal, but not salivary, 
radioiodine accumulation in wild type (WT) mice and in our thyroid-targeted RET/PTC1 
(Tg-PTC1) thyroid cancer mouse model. Our findings encourage the investigation of 17-
AAG derivative pharmacological agents to increase the efficacy of radioiodine therapy in 




 Material and Methods 
 
Animals and Treatment 
The study protocol (2009A0118) was approved by our Institutional Animal Care and Use 
Committee that oversees the responsible use of animals in university research and 
instructional activities. All research activities were conformed to the statutes of the 
Animal Welfare Act and the guidelines of the Public Health Service as issued in the 
Guide for the Care and Use of Laboratory Animals (revised 1996). Tg-PTC1 mice were 
generated in the FVB/N background, and all Tg-PTC1 mice developed thyroid tumors by 
one month of age (Cho et al. 1999; Jhiang et al. 1996).  For T3-bTSH experiments, mice 
were supplemented with 12 µg/ml T3 in their drinking water daily. On day 5, mice 
received a single intraperitoneal (i.p.) injection of bTSH in 200 µl 1% BSA/PBS and after 
16 hr the mice were subjected to SPECT imaging, or sacrificed for ex vivo gamma 
counting, as described below. The bTSH dosages utilized are reported at the result 
section. 
Two different experimental plans were employed for 17-AAG (National Cancer Institute: 
NCI 330507) experiments. We started with the protocol of using T3-bTSH treated mice  
i.p. injected with a single dose of 40 mg/kg 17-AAG (the highest dose used in mice 
reported in NCI Investigator brochure, 2004) and performed SPECT imaging at 2 hr post 
17-AAG injection. We later modified the protocol using mice neither treated with T3 nor 
bTSH (non-treated mice) i.p. injected with a single dose of 30 mg/kg 17-AAG and 




In vivo multi-pinhole SPECT imaging  
Small animal SPECT imaging was performed using the X-SPECT preclinical platform 
(Gamma Medica, CA, USA) equipped with 2 gamma cameras, each mounted with a 
multiple pinhole collimator with 1 mm aperture. After i.p. injection of 100-150 μCi 
Na123I (t1/2= 13.3 hr) or Na99mTcO4 (t1/2= 6.01 hr) in saline, mice were anesthetized using 
isofluorane inhalation and immobilized on the animal bed. For subsequent calibration of 
radioactivity in target tissues at various times, a 0.25 ml eppendorf tube containing a 
known amount of the same radionuclide was included as a decay control (DC). SPECT 
imaging was acquired with 32 projections, each for 50 sec on a 30 mm radius of rotation. 
SPECT images were acquired at 1, 6, and 24 hr post Na123I injection or 1 hr post Na99m 
TcO4 injection.  
 
Ex vivo gamma counting  
Following T3-bTSH treatment, animals were i.p. injected with 20-40 μCi Na123I in saline. 
Animals were sacrificed at 6 hr post Na123I injection, and thyroid gland, salivary gland 
and liver were harvested and their radioactivity measured with a gamma counter (Perkin 
Elmer, MA, USA) along with a known activity of Na123I as a standard for quantification.  
 
Calculation of thyroidal and salivary radioiodine accumulation 
The total injected dose was calculated by subtracting the post-injected syringe counts 
from the pre-injected syringes counts. Using the Amira 3.1 software (Gamma Medica, 
CA, USA), region of interest (ROI) was manually drawn over the thyroid gland, salivary 
gland, or decay control on xy, yx, and xz-planes, and the total radioactivity in the 3D 
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region defined by the three selected planes was automatically determined. Thyroidal and 
salivary radioiodine accumulation were calibrated by decay control counts at each time 
point and reported as the percentage of injected dose (%ID). 
 
Statistical Analysis 
As many of the experiments measured thyroidal radioiodine accumulation in mice over 
time, linear mixed models were used to take account of the dependency of observations 
within the same animals. To ensure unbiased hypothesis tests, we used a covariance 
structure estimation method for small samples that avoids underestimation of 
experimental error. Two sample t-tests were used for simple two group comparisons and 
Holm’s step down procedure (Holm 1979) was used to adjust for multiple comparisons. 
P-values <.05 for single comparisons or after adjustment for multiple comparisons were 





Temporal dynamics of radioiodine accumulation in thyroid and salivary glands 
evaluated by 3D SPECT functional imaging 
Thyroidal iodide accumulation is largely the sum of NIS-mediated iodide uptake 
along with iodide retention by iodide organification. In comparison, salivary glands 
accumulate iodide through NIS-mediated iodide uptake but they lack iodide 
organification. The temporal dynamics of 123I accumulation in thyroid and salivary glands 
in WT mice was examined by non-invasive SPECT nuclear imaging (Fig. 1). At 1 hr post 
Na123I injection (t1), 123I accumulation was evident in both thyroid and salivary glands. 
At 6 hr post Na123I injection (t6), 123I accumulated in the thyroid gland was further 
increased due to continued iodide uptake and organification. However, 123I accumulated 
in the salivary gland was decreased due to lack of iodide organification and decreased 123I 
in the blood circulation. At 24 hr post Na123I injection (t24), 123I accumulation in the 
thyroid gland continued to increase when normalized by physical decay. Conversely, no 
123I accumulation was detected in the salivary gland at t24, suggesting that 123I was 
completely cleared from the blood circulation by excretion or tissue uptake in other 
tissues such as the thyroid. Consequently, thyroidal radioiodine accumulation at t24 was 
mainly contributed by iodide retention. 
Several mice were subjected to SPECT imaging in the same experimental settings 
as stated above. The amount of 123I accumulation in the thyroid (%ID) varied extensively 
among mice and the degree of 123I accumulation at t6 was not always near maximum, i.e. 
to the similar extent seen at t24 (Fig. 2). Thyroidal %ID at t1, t6, and t24 for each mice 
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studied are shown in Table 1 (t1: 0.63-6.45%, mean= 2.07%; t6: 1.59-23.21%, mean= 
8.88%; and t24: 1.48-24.66%, mean= 11.55%). Albeit our small sample number, mice of 
14-15 months of age tended to have lower iodide influx as indicated by thyroidal %ID at 
t1. Mice of 2-3 months old appeared to have lower iodide retention ability as indicated by 
lower ratios of t6 or t24 over t1 thyroidal %ID. This may be at least in part contributed by 
their faster renal clearance rate as shown by a sharper decrease in 123I accumulation in 
salivary gland at t6 versus t1 (t6/t1 %ID: 2-3 month: 0.1-0.3, mean= 0.22, N=3; > 6 
month: 0.73-1.01, mean= 0.86, N=4).  These findings warrant further study using a larger 
cohort. 
 
The extent of single dose bTSH induced thyroidal radioiodine accumulation in T3-
supplemented mice is less than that induced by continuous stimulation of 
endogenous mouse TSH in non-treated mice  
To examine the effect of exogenous bTSH on temporal dynamics of thyroidal 
radioiodine accumulation in the absence of endogenous mouse TSH (mTSH), 
endogenous mTSH was suppressed by T3 supplementation in WT mice. As shown in Fig. 
2, thyroidal radioiodine accumulation was diminished in all mice that underwent T3 
supplementation (t1: 0.18-1.06%, mean= 0.49%; t6: 0.26-0.59%, mean= 0.41%; t24: 0-
0.2%, mean= 0.06%, N=4), despite extensive variability of thyroidal radioiodine 
accumulation seen in non-treated mice (N=11). This data confirms that our T3 
supplementation protocol is sufficient to suppress endogenous mTSH induced thyroidal 
radioiodine accumulation, regardless of age and gender.  
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In mice treated with 6, 30, or 60 μg of bTSH at day 5 of T3-supplementation, 
thyroidal radioiodine accumulation was increased in a dose-dependent manner (data not 
shown). Further increase of bTSH to 90 μg did not further increase (p-value=0.71) 
thyroidal radioiodine accumulation as determined by ex vivo gamma counting of thyroids 
at 6 hr post Na123I injection (Fig. 3A). As shown in Fig. 2, thyroidal radioiodine 
accumulation averaged across time was significantly increased (p-value= 0.0007) by a 
single dose of 60 μg bTSH in T3 supplemented mice (t1: 0.34-1.99%, mean= 0.93%; t6: 
1.22-2.84%, mean= 2.01%; t24: 1.97-3.36%, mean= 2.46%, N=5). However, 
thyroidal %ID in T3-bTSH treated mice was much lower (p-value= 0.027) than that in 
non-treated mice. This is most likely due to the short half-life of bTSH (< 3hr, Guyot et 
al. 2007), such that a single dose of 60 µg bTSH in T3 supplemented mice is not 
sufficient to induce thyroidal radioiodine accumulation comparable to non-treated mice 
which had continuous low-level stimulation of endogenous mTSH.  
 
The extent and duration of thyroidal radioiodine accumulation induced by bTSH is 
less in Tg-PTC1 mice than that in wild type mice  
 Tg-PTC1 mice can serve as a preclinical animal model to examine factors that 
modulate radioiodine accumulation in thyroid tumors. We previously reported that 
thyroidal radioiodine accumulation in Tg-PTC1 mice is decreased compared to WT mice 
at 6 hr post Na125I injection when normalized with tissue weight despite of elevated 
serum TSH level in Tg-PTC1 mice (Cho et al. 1999). This is consistent with clinical 
findings that malignant thyroid tumors are typically “cold” nodules. Our pilot study 
showed that thyroidal radioiodine accumulation was also suppressed by T3 
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supplementation in Tg-PTC1 mice (data not shown). To compare the responsiveness of 
WT and Tg-PTC1 mice to exogenous bTSH toward induction of thyroidal radioiodine 
accumulation, 123I accumulation at t6 was evaluated in T3 supplemented mice injected 
with a single dose of bTSH. As shown in Fig. 3A, the extent of bTSH induced thyroidal 
radioiodine accumulation at t6 in Tg-PTC1 mice (1.6-2.5%, mean= 2.04%, N=4) was 
significantly lower (p-value= 0.001) than that in WT mice (8.9-16.3%, mean= 12.44%, 
N=4) without normalization for thyroid gland volume or weight. However, the size of 
thyroid glands in Tg-PTC1 mice was consistently larger than that in WT mice.  
To compare the duration of bTSH-induced NIS activity between WT mice and 
Tg-PTC1 mice, Na99mTcO4, which cannot be organified, was used to evaluate NIS-
mediated radionuclide influx at 17 hr or 41 hr post bTSH administration. As shown in Fig. 
3B, thyroidal %ID of Na99mTcO4 was modestly decreased (p-value= 0.28) at 41 hr 
compared to 17 hr post bTSH administration in WT mice (17 hr: 1.27-1.54%, mean= 
1.41%; 41 hr: 0.23-1.50%, mean= 0.93%, N=3). In comparison, thyroidal %ID of 
Na99mTcO4 was significantly decreased (p-value= 0.0076) at 41 hr in all three Tg-PTC1 
mice examined (17 hr: 1.7-2.60%, mean= 2.01%,; 41 hr: 0.00-0.57%, mean= 0.32%, 
N=3). Indeed, statistical analysis by linear mixed model showed that the difference of 
NIS activity between 17 hr and 41 hr post bTSH administration for Tg-PTC1 mice was 
much more evident (p-value= 0.014) than that for WT mice. Taken together, thyroid 
tumor bearing thyroid glands of Tg-PTC1 mice not only were less responsive to bTSH in 
the induction of radioiodine accumulation; the duration of NIS induction was also much 
shorter than normal thyroids in WT mice. It is interesting to note that thyroidal %ID of 
Na99mTcO4 at 17 hr post bTSH injection in Tg-PTC1 mice was higher compared to WT 
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mice, suggesting that the number of thyroid follicular cells responsive to bTSH at an 
early time point in Tg-PTC1 mice is much more than that in WT mice. This phenomenon 
can be explained by increased proliferation of thyroid follicular cells (Cho et al. 1999) 
and the much  larger size of thyroids observed in Tg-PTC1 mice. 
 
The area under time-activity curve of thyroid in wild type mice is markedly 
increased by 30 mg/kg 17-AAG  
None of the T3-bTSH mice injected with a single dose of 40 mg/kg 17-AAG 
survived during SPECT imaging acquisition (N=3, data not shown), indicating the 
experimental condition was not tolerable by the mice. We then examined the effect of 30 
mg/kg 17-AAG in non-treated mice which had Na123I injection at 3 hr post 17-AAG 
injection (see the top panel of Fig. 4). Three experimental trials with identical design 
were performed to compare temporal radioiodine accumulation between DMSO and 17-
AAG treated mice. As shown in Fig 4, thyroidal radioiodine accumulation at t24 in 17-
AAG treated mice was much higher (p-value= 0.15) than DMSO-treated mice in each 
experimental trial (DMSO vs. 17-AAG: 5.42% vs. 9.22%; 20.66% vs. 65.88%; 8.07% vs. 
55.05%), despite extensive variations of thyroidal %ID among different experimental 
trials. Conversely, thyroidal radioiodine accumulation at t1 was not increased (p-value= 
0.98) by 17-AAG treatment (DMSO vs. 17-AAG: 3.58% vs. 4.02%; 1.18% vs. 0.63%; 
3.24% vs. 3.44%). These results indicate that 17-AAG markedly increases iodide 
retention although it has little effect on NIS-mediated iodide influx.  
The average of thyroidal %ID at t1, t6, and t24 among three experimental trials as 
well as the average ratio of thyroidal %ID at t6 or t24 versus t1 in each experimental trial 
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are shown in Table 2. Iodide retention ability in WT mice was moderately increased by 
17-AAG at t6 (~ 2 fold), and further increased at t24 (~ 4 fold) as compared to DMSO 
treated mice. Consequently, the exposure of the thyroid to radioiodine over time was 
markedly increased by 17-AAG as defined by the area under time-activity curve (AUC). 
Indeed, while the value of AUC varied greatly among experimental trials (DMSO: 224.4 
± 133.2, N=3; 17-AAG: 583.1 ± 362.1, N=3), the fold increase in AUC by 17-AAG 
calculated in each experimental trial ranged from 1.55 to 3.96. Taken together, the effect 
of 17-AAG on increasing radioiodine accumulation in cultured thyroid cells is validated 
in WT mice using temporal SPECT imaging. Furthermore, 17-AAG did not appear to 
have a effect on salivary %ID (data not shown). 
    
The area under time-activity curve of thyroid tumor in Tg-PTC1 mice is markedly 
increased by 30 mg/kg 17-AAG  
We next examined the effect of 30 mg/kg 17-AAG on thyroidal radioiodine 
accumulation in thyroid tumor bearing thyroid glands of Tg-PTC1 mice. While WT mice 
were tolerant of 30mg/kg 17-AAG treatment, two out of four Tg-PTC1 mice did not 
survive through SPECT imaging acquisition. However, as shown in Fig. 5, both of the 
remaining Tg-PTC1 mice treated with 17-AAG had evident increase of thyroidal 
radioiodine accumulation compared to mice treated with DMSO at t24 (DMSO vs. 17-
AAG: 3.50% vs. 25.89%; 2.53% vs. 19.23%). Similar to WT mice, 17-AAG appeared to 
increase radioiodine retention rather than radioiodide influx in Tg-PTC1 mice. As shown 
in Table 2, iodide retention was moderately increased by 17-AAG at t6 (~ 1.5 fold), yet it 
was further increased at t24 (~ 4 fold) as calculated by the average ratios of 
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thyroidal %ID at t6 or t24 versus t1 in each experimental trial. The value of AUC was 
less variable between the two experimental trials in Tg-PTC1 mice (DMSO: 148.8 ± 44.3, 
N=2; 17-AAG: 442.6 ± 62.7, N=2), and the fold increase in AUC by 17-AAG in the two 
experimental trials were 2.21 and 4.14. Thyroidal iodide retention ability in 17-AAG 
treated Tg-PTC1 mice (t24/t1 %ID= 2.6 ± 0.6) was much lower than that in WT mice 
(t24/t1 %ID= 15.7 ± 0.9) at t24, yet the fold increase of iodide retention ability by 17-
AAG was comparable between Tg-PTC1 mice and WT mice at t24. Taken together, the 
effect of 17-AAG on increasing thyroidal radioiodine accumulation is confirmed in a 





In this study, we quantified temporal radioiodine accumulation in both thyroid 
and salivary glands modulated by T3, bTSH and/or 17-AAG in mice using SPECT 
functional imaging. By comparing temporal dynamics of radioiodine accumulation 
between salivary and thyroid glands, we found that administered radioiodine was almost 
completely cleared from blood circulation after 24 hr, and that iodide organification 
contributes greatly to thyroidal radioiodine accumulation over time. The extent of 
thyroidal radioiodine accumulation stimulated by a single dose of exogenous bTSH in T3 
supplemented mice was much less than that in non-treated mice, justifying the clinical 
use of multiple doses of rhTSH or the merit of T4 withdrawal in thyroid cancer patients 
prior to radioiodine therapy. Furthermore, the extent and duration of radioiodine 
accumulation stimulated by bTSH was reduced in thyroid tumor bearing thyroid glands 
of Tg-PTC1 mice compared to the thyroids in WT mice. Lastly, 17-AAG significantly 
increased thyroidal exposure of radioiodine over time in our Tg-PTC1 preclinical thyroid 
cancer mouse model, which encourages the study of 17-AAG derivatives not only as 
novel chemotherapeutic agents to impede tumor progression but also to improve 
radioiodine therapy in patients with thyroid cancer. Optimally, 17-AAG derivatives could 
permit those tumors with low radioiodine accumulation to become amenable to 
radioiodine treatment and allow for those tumors with normal radioiodine accumulation 
to be affectively treated with lower radioiodine activities.  
Salivary gland dysfunction is the most frequent non-thyroidal complications of 
radioiodine therapy for patients with thyroid cancer (Kloos 2009). A better understanding 
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of the temporal dynamics of radioiodine accumulation in the thyroid and salivary glands 
may lead to strategies to mitigate radioiodine-induced salivary gland damage without 
compromising the efficacy of thyroid cancer radioiodine therapy. A recent study showed 
that the time required to reach maximal accumulation of 99mTcO4 uptake in thyroid glands 
is shorter than that in salivary glands of C57 BL6/6J mice (Franken et al. 2010). This 
difference could be explained by higher NIS transport activity and/or smaller NIS-
expressing epithelial cell-delimiting compartments of the thyroid, i.e. thyroid colloid 
versus salivary acini and duct lumens. Similarly, the rate of decrease in 99mTcO4 
accumulation is faster in the thyroid than in the salivary gland after administration of 
competitive inhibitors (Franken et al. 2010). In the current study, we showed that salivary 
gland %ID was 1.02-5.75 fold higher than thyroid %ID at t1 (see Table 1), which has 
been reported by others (Franken et al. 2010; Zuckier et al. 2004) and is anticipated by 
the larger size of the salivary gland. Indeed, voxel counts in the selected ROI of salivary 
were 1.93-9.38 fold higher than those of the thyroid at t1 (data not shown), although 
functional voxel counts in selected ROI may not exactly reflect anatomic volume of the 
target tissue. Interestingly, the normalized means (total signal intensity counts divided by 
voxel counts) of salivary glands at t1 were lower than those of the thyroids 
(salivary/thyroid= 0.47-0.94 with a mean of 0.68), indicating that NIS expression/activity 
per anatomic unit is lower in salivary gland compared to the thyroid gland. Salivary 
normalized means at t1 were quite comparable among mice (62-80 with a mean of 72), 
yet thyroid normalized means at t1 varied greatly among mice (66-163 with a mean of 
113). Thus, NIS activity per anatomic unit in the salivary gland does not appear to be 
modulated by gender or age among different mice.  
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It is of interest to note that the ratio of salivary %ID versus thyroidal %ID at t1 
appeared to be greater in male (1.84-4.63, mean= 3.47, N=3) than in female (1.02-2.29, 
mean= 1.59, N=3) mice and seemed to increase with age (2-3 month: 1.02-3.95, mean= 
2.07, N=4; 6-7 month: 2.29-4.63, mean= 3.46, N=2; 14-15 month: 5.11-5.75, mean= 5.43, 
N=2). This finding is consistent with the reports that total accumulation of 131I uptake in 
submaxillary glands is greater in male than in females in several strains of mice (Llach et 
al. 1960). The reasons underlying the increase of salivary/thyroid %ID ratio with age is 
unknown as the variations of salivary %ID or thyroid %ID did not correlate with age. If 
the dependence of the ratio of salivary %ID versus thyroidal %ID at t1 on gender and age 
holds true in humans, and if salivary gland damage occurs at an early stage of 131I 
exposure, we would anticipate that male and elder patients would experience more 
salivary dysfunction after radioiodine therapy. Finally, 123I accumulation was not 
detectable in the salivary gland at t24 in all mice of 2-20 months old. This is consistent 
with the report that radioiodine in blood circulation was completely excreted by 19 hr 
post Na125I injection in CD1 mice (Zuckier et al. 2004).  
It has been shown that normal women had slightly higher thyroidal uptake than 
men at both 2 hr and 24 hr post 131I administration. Furthermore, thyroidal uptake 
decreased slightly when subjects were aged more than 40 years old compared to those 
younger than 40 years at both 2 hr and 24 hr post 131I administration (González E et al. 
2008). In another study, thyroidal uptake was shown to increase with age to a maximum 
at about 40 years old, then decreased afterwards at both 4 hr and 24 hr post 131I 
administration (Schober et al. 1976). Despite our small sample number, we did observe 
that female mice had higher thyroidal radioiodine accumulation compared to that of male 
19 
 
mice at t1 (female: 0.63-6.45%, mean= 2.74%; male: 0.90-2.94%, mean= 1.77%), t6 
(female: 1.59-23.21%, mean= 11.39%; male: 2.85-18.45%, mean= 6.79%) and t24 
(female: 1.48-24.66%, mean= 13.27%; male: 3.62-21.26%, mean= 10.41%). Taken 
together, it would be interesting to investigate whether the minimal radioactivity needed 
to ablate thyroid remnant in low-risk patients could be stratified by gender and age based 
on their differences in the magnitude of thyroidal radioiodine accumulation.  
While rhTSH administration has been shown to be equally effective compared to 
thyroid hormone withdrawal in preparation of low-risk patients for post-operative thyroid 
remnant ablation (Chianelli et al. 2009; Elisei et al. 2009; Pacini et al. 2006; Tuttle et al. 
2010), it remains uncertain whether rhTSH is equally effective in treating high-risk 
patients with known residual cancer. The level and duration of serum TSH levels required 
for effective ablation of thyroid remnant could be very different from that for residual 
cancer and may vary depending on various somatic tumor mutations that affect 
radioiodine accumulation. Indeed, Potzi and colleagues reported that a higher 
radioactivity of 131I is required to achieve comparable radioiodine accumulation in 
thyroid cancer metastases in patients administered radioiodine after rhTSH versus thyroid 
hormone withdrawal preparation (Potzi et al. 2006). Our current study showed that 
thyroidal radioiodine accumulation in T3-bTSH mice was much lower than that in non-
treated mice suggesting that the duration of exposure to TSH is important to promote 
desirable thyroidal radioiodine accumulation. We also showed that thyroid tumor bearing 
thyroid glands in Tg-PTC1 mice were less responsive to bTSH induced thyroidal 
radioiodine accumulation than normal thyroids in WT mice. Taken together, thyroid 
cancer foci may require higher 131I activity for treatment as opposed to normal thyroid 
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remnants and longer duration of elevated TSH level may be required to achieve the 
desirable 131I activity in thyroid cancer foci. Accordingly, thyroid cancer mouse models 
can be invaluable to examine the concepts of magnitude and duration of serum TSH 
elevation required to confer sufficient radioiodine accumulation in thyroid tumors.  
Findings using cultured cells do not always translate into preclinical animal 
models or patients. For example, leptin decreases radioiodine uptake activity in FRTL-5 
immortalized rat thyroid cells (Isozaki et al. 2004) and rat thyroid slices (de Oliveira et al. 
2007), yet it increases thyroidal radioiodine uptake activity in live rats (de Oliveira et al. 
2007). The discordance is most likely explained by tissue microenvironments and/or 
systemic effects that do not exist in isolated cultured cell system. In this study, we 
confirmed that 17-AAG increases thyroid exposure to radioiodine over time in WT mice 
as well as Tg-PTC1 transgenic mice carrying thyroid tumors. The fact that 17-AAG did 
not increase thyroidal radioiodine accumulation at t1, but did at t6 and t24, indicates that 
17-AAG has little effect on NIS-mediated radioiodine influx but mainly acts on iodide 
retention/organification. This result is consistent with our previous finding that 17-AAG 
increases radioiodine accumulation by decreasing iodide efflux in cultured cells (Marsee 
et al. 2004). Nevertheless, before this finding can be translated into clinical trials, a few 
important issues need to be addressed. Are there any differences in the effects of Hsp90 
inhibitors on thyroid tumors derived from various genetic abnormalities, such as B-
RAFV600E mutation? Do all Hsp90 inhibitors increase thyroidal radioiodine 
accumulation? Which Hsp90 inhibitor has the desired pharmacokinetic and 
pharmacodynamic profiles? What is the optimal dose, duration, and timing of Hsp90 
inhibitor treatment to increase the efficacy of radioiodine therapy? Is the magnitude of 
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increased radioiodine accumulation by Hsp90 inhibitors sufficient to meaningfully 
improve the efficacy of radioiodine therapy? Finally, while not immediately needed for 
Hsp90 inhibitor clinical application, what are the molecular targets of this treatment in 
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Figure 1. Temporal dynamics of thyroidal and salivary radioiodine accumulation in 
wild type mouse. A 7 month old male wild type mouse was injected with ~150 µCi 
Na123I and subjected to SPECT imaging at 1(t1), 6(t6) and 24 hr(t24) post Na123I 
injection. At t1, thyroidal radioiodine accumulation was mainly contributed by NIS-
mediated 123I influx from blood circulation. At t6, thyroidal radioiodine accumulation 
was contributed by continuous 123I influx as well as 123I organification/retention. At t24, 
thyroidal radioiodine accumulation was mainly contributed by 123I 
organification/retention as NIS-mediated 123I uptake from blood circulation in the 
salivary gland was observed at t1 and t6, but not at t24. Thy: thyroidal functional image; 
Sal: salivary functional image; DC: decay control functional image. Decay control serves 
to normalize counts of thyroidal radioiodine accumulation at each time-point for 
quantification purposes. The color bar indicates radioiodine signal intensity increases 
from 20 (black) to 500 (red) in arbitrary units.  
 
Figure 2. The extent of induced thyroidal radioiodine accumulation by one dose of 
60 μg bTSH in T3 supplemented mice is much less than that induced by continuous 
endogenous mTSH in non-treated mice. WT mice were given 12 µg/ml T3 in drinking 
water daily. On day 5, mice were injected with one dose of 60 μg bTSH (T3-60 µg 
bTSH; N=5). Na123I (100-150 µCi) was administered into mice at 16 hr post bTSH 
injection. SPECT images were taken at 1(t1), 6(t6) and 24 hr(t24)  post Na123I injection. 
For comparison, T3 mice (N=4) and non-treated mice (N=11) were subjected to SPECT 
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imaging as well. In T3 mice, thyroidal radioiodine accumulation was almost undetected 
(p-value= 0.0017), confirming that T3 supplementation for 5 consecutive days is 
sufficient to suppress endogenous TSH induced thyroidal radioiodine accumulation. 
While one dose of 60 μg bTSH was sufficient to induce some extent of thyroidal 
radioiodine accumulation, the extent of 60 μg bTSH induced radioiodine accumulation 
was far less (p-value= 0.027) than that of non-treated mice.  
 
Figure 3. The extent of thyroidal radioiodine accumulation and temporal duration 
of NIS-mediated thyroidal Na99mTcO4 influx activity induced by bTSH is less in Tg-
PTC1 mice than that in wild type mice. (A) 7 month old WT and 4 month old Tg-PTC1 
mice were given 12 µg/ml T3 in drinking water daily. On day 5, mice were injected with 
either one dose of 60 or 90 μg bTSH. Na123I (20-40 µCi) was injected into mice at 16 hr 
post bTSH injection. At 6 hr(t6) post Na123I injection, mice were euthanized and thyroids 
were harvested and subjected for counting of activity by a gamma counter. Statistical 
analysis showed that WT mice had significantly higher (p-value= 0.001) thyroidal 
radioiodine accumulation at t6 than Tg-PTC1 mice, while there was no significant 
difference (p-value= 0.71) between 60 or 90 µg bTSH induced thyroidal radioiodine 
accumulation in both WT and Tg-PTC1 mice. (B) T3-supplemented WT and Tg-PTC1 
mice were administered with one dose of 60 μg bTSH. Na99mTcO4 (100 µCi), a substrate 
of NIS yet could not be organified by thyroid, was first injected into mice 16 hr post 
bTSH injection and SPECT images were acquired at 1 hr post Na99mTcO4 injection, i.e. at 
17 hr post bTSH injection. A second dose of Na99mTcO4 (100 µCi) was injected into mice 
40 hr post bTSH injection and SPECT images were acquired at 1 hr post the second 
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Na99mTcO4 injection, i.e. at 41 hr post bTSH injection. Two out of three WT mice had 
comparable NIS-mediated 99mTcO4 influx activity at the two different time points, 
whereas all three Tg-PTC1 mice had decreased NIS-mediated 99mTcO4 influx activity at 
later time point. The difference in duration of NIS-mediated thyroidal 99mTcO4 influx 
activity induced by single dose of bTSH between Tg-PTC1 mice and WT mice was 
statistically significant (p-value= 0.014).  
 
Figure 4. The area under time-activity curve (AUC) of thyroid in wild type mice is 
markedly increased by 30 mg/kg 17-AAG. WT mice (15-18 months) were weighed and 
injected with 30 mg/kg 17-AAG in 50 μl DMSO. Na123I (100-150 µCi) was injected into 
mice at 3 hr post 17-AAG injection. SPECT images were acquired at t1(4), t6(9) and 
t24(27) post Na123I injection (time post 17-AAG injection). At t1, the extent of thyroidal 
radioiodine accumulation was quite comparable between DMSO versus 17-AAG treated 
mice suggesting that 17-AAG had minimal effect on thyroidal iodide influx. However, at 
t24, the extent of thyroidal radioiodine accumulation was markedly increased (p-value= 
0.15) in 17-AAG treated mice versus that in DMSO treated mice, suggesting that 17-
AAG increases iodide retention ability. Consequently, the exposure of thyroid with 
radioiodine over time was markedly increased by 17-AAG as defined by the AUC. 
 
Figure 5. The area under time-activity curve (AUC) of thyroid tumor in Tg-PTC1 
mice is markedly increased by 30 mg/kg 17-AAG. Tg-PTC1 mice (15-21 months) were 
weighed and injected with 30 mg/kg 17-AAG in 50 μl DMSO. Na123I (100-150 µCi) was 
injected into mice at 3 hr post 17-AAG injection. SPECT images were acquired at t1(4), 
30 
 
t6(9) and t24(27) post Na123I injection (time post 17-AAG injection). At t24, the 
difference in the extent of increased thyroidal radioiodine accumulation was evidently 
enhanced in 17-AAG treated mice compared to that in DMSO treated mice at least in part 
due to the decreased thyroidal %ID by DMSO at t24 in Tg-PTC1 mice. As a result, AUC 
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Table 1. Temporal dynamics of thyroidal and salivary radioiodine accumulation in 




Gender Age (mon) t1 t6 t24 t6/t1 t24/t1 t1 t6 t6/t1
M 2 1.49 2.88 3.62 1.94 2.43 2.74 0.83 0.30
M 3 1.64 3.15 8.30 1.93 5.07 6.47 1.7 0.26
M 7 2.94 18.45 21.26 6.27 7.22 13.62 9.92 0.73
M 14 0.90 5.29 13.06 5.88 14.52 4.59 3.94 0.86
M 15 1.12 8.14 11.60 7.25 10.33 6.46 6.54 1.01
F 3 6.45 12.74 10.46 1.98 1.62 6.57 0.69 0.10
F 4 0.63 1.59 1.48 2.51 2.34 0.93 1.37 1.48








Table 2. Effect of 17-AAG on thyroidal radioiodine accumulation in wild type and 
Tg-TPC1 mice 
 
t1 t6 t24 6hr/1hr 24hr/1hr AUC* 
DMSO 2.6 ± 1.3 9.3 ± 4.1 11.2 ± 7.9 3.6 ± 0.2 4.3 ± 1.6 224.4 ± 133.2
17-AAG 2.7 ± 1.8 13.0 ± 6.6 43.4 ± 30.1 6.3 ± 3.4 15.7 ± 0.9 583.1 ± 362.1
DMSO 7.4 ± 5.6 8.8 ± 5.1 3.0 ± 0.7 1.3 ± 0.3 0.6 ± 0.6 148.8 ± 44.3















)( ; f(t): thyroidal %ID; 
d(t): time(hour) 
 
 
